The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
An open-label, multicenter, phase 2 study to evaluate the safety and efficacy of BB-1701, a novel antibody drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2), in previously treated patients with HER2-positive (HER2+) or HER2-low unresectable or metastatic breast cancer (BC).
 
Aditya Bardia
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca; Genentech; Genentech/Roche (Inst); Gilead Sciences; Gilead Sciences (Inst); Innocrin Pharma (Inst); Lilly; Lilly (Inst); Menarini; Menarini (Inst); Merck; Mersana; Novartis; Novartis (Inst); Pfizer; Pfizer (Inst); Radius Health (Inst); Sanofi
Research Funding - AstraZeneca/Daiichi Sankyo (Inst); Genentech (Inst); Immunomedics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Radius Health (Inst); Sanofi (Inst)
 
Ciara Catherine O'Sullivan
Honoraria - AstraZeneca (Inst); Medscape (Inst); Seagen (Inst); Seagen (Inst)
Research Funding - Academic & Community Cancer Research United (Inst); Bavarian Nordic (Inst); Eisai (Inst); Genentech (Inst); Lilly (Inst); nference (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst); Tesaro (Inst)
Patents, Royalties, Other Intellectual Property - nFerence Astra Zeneca (Inst)
 
Reshma L. Mahtani
Consulting or Advisory Role - Agendia; Amgen; Daiichi Sankyo/Astra Zeneca; Eisai; Genentech/Roche; Gilead Sciences; Hologic/Biotheranostics; Lilly; Merck; Novartis; Pfizer; Puma Biotechnology; Sanofi; Sermonix Pharmaceuticals; Stemline Therapeutics
Speakers' Bureau - Seattle Genetics/Astellas
Research Funding - Gilead Sciences (Inst)
Travel, Accommodations, Expenses - Agendia; Amgen; AstraZeneca; bioTheranostics; Daiichi Sankyo/Lilly; Eisai; Genentech/Roche; Lilly; Merck; Novartis; Pfizer; Puma Biotechnology; Sanofi; Seagen
 
Sibel Blau
Employment - Northwest Medical Specialties
Leadership - Northwest Medical Specialties; Quality Cancer Care Alliance
Stock and Other Ownership Interests - All4cure (I); Northwest Medical Specialties
Honoraria - American Journal of Managed Care; Cardinal Health; Novartis; Puma Biotechnology
Consulting or Advisory Role - Billion to One; IntegraConnect
Research Funding - Northwest Medical Specialties
Expert Testimony - Northwest Medical Specialties
Travel, Accommodations, Expenses - Northwest Medical Specialties; Quality Cancer Care Alliance
Other Relationship - All4Cure (I); Exigent Research; Northwest Medical Specialties; Quality Cancer Care Alliance
 
Nihal E. Abdulla
No Relationships to Disclose
 
Azka Ali
Honoraria - Tersera
Consulting or Advisory Role - AstraZeneca; Guardant Health; Guardant Health
Research Funding - AstraZeneca/Daiichi Sankyo (Inst); Symbiosys
Travel, Accommodations, Expenses - Tersera
 
Rani Bansal
Consulting or Advisory Role - Hologic
 
Janelle Marie Meyer
Research Funding - Abbvie (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); BillionToOne (Inst); BillionToOne (Inst); Biodesix (Inst); Celcuity (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Janssen (Inst); Lilly (Inst); Mirati Therapeutics (Inst); Natera (Inst); Tempus (Inst); VastBiome (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from Up To Date
Travel, Accommodations, Expenses - Exigent Research
 
Mridula Annette George
Honoraria - Natera
Consulting or Advisory Role - OBI Pharma; Seagen
Research Funding - Incyte; Oncolytics
Travel, Accommodations, Expenses - OBI Pharma; OBI Pharma
Other Relationship - Oncology Learning Network
 
Hyo S. Han
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca; Immunomedics; Novartis
Research Funding - Abbvie (Inst); Arvinas (Inst); Celcuity (Inst); Department of Defense (Inst); G1 Therapeutics (Inst); GlaxoSmithKline (Inst); Marker Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Phoenix Pharmaceuticals (Inst); Pionyr (Inst); QuantumLeap Health (Inst); Seagen (Inst); Senhwa Biosciences (Inst); Zymeworks (Inst)
 
Timothy J. Pluard
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Carrick Therapeutics; Daiichi Sankyo/Astra Zeneca; DualityBio; Gilead Sciences; Jazz Pharmaceuticals; Kestrel Therapeutics; Merck; Novartis; Pfizer; Scorpion Therapeutics; Seagen; Sermonix Pharmaceuticals; Stemline Therapeutics
Speakers' Bureau - AstraZeneca; Gilead Sciences; SeaGen; Stemline Therapeutics
Research Funding - Arvinas; AstraZeneca/Daiichi Sankyo (Inst); Dantari (Inst); G1 Therapeutics (Inst); H3 Biomedicine (Inst); HiberCell (Inst); Novartis; Novartis; Olema Pharmaceuticals (Inst); Orinove (Inst); Pfizer (Inst); Sanofi (Inst); Scorpion Therapeutics; Seagen (Inst); Zymeworks (Inst)
 
Steven W. Papish
No Relationships to Disclose
 
Jason Michael Jones
Travel, Accommodations, Expenses - AstraZeneca
 
Yuanxin Rong
Employment - Eisai
 
Guozhi Gao
Employment - Eisai
Stock and Other Ownership Interests - Pfizer
Travel, Accommodations, Expenses - Eisai
 
Hope S. Rugo
Consulting or Advisory Role - Daiichi Sankyo; Eisai; Mylan; Napo Pharmaceuticals; Puma Biotechnology
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Hoffmann-La Roche AG/Genentech, Inc (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); OBI Pharma (Inst); Pfizer (Inst); Stemline Therapeutics (Inst); Taiho Oncology (Inst); Veru (Inst)